NASDAQ:DRRXDURECT Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.24 0.00 (0.00 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$2.18Now: $2.24▼$2.3050-Day Range$2.14MA: $2.40▼$2.6652-Week Range$0.64Now: $2.24▼$3.95Volume1.45 million shsAverage Volume1.57 million shsMarket Capitalization$439.10 millionP/E RatioN/ADividend YieldN/ABeta2.18 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingDURECT has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.53, DURECT has a potential upside of 102.0% from its current price of $2.24.Amount of Analyst CoverageDURECT has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesDURECT has received 295 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDURECT has received 200 “underperform” votes. (Add your “underperform” vote.)Community SentimentDURECT has received 59.60% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote “Outperform” if you believe DRRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDURECT does not currently pay a dividend.Dividend GrowthDURECT does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DURECT insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $240,129.00 in company stock.Percentage Held by InsidersOnly 10.20% of the stock of DURECT is held by insiders.Percentage Held by Institutions49.93% of the stock of DURECT is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for DURECT are expected to grow in the coming year, from ($0.16) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DURECT is -18.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DURECT is -18.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDURECT has a P/B Ratio of 18.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.61 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRRX Previous Symbol CUSIPN/A CIK1082038 Webwww.durect.com Phone408-777-1417Debt Debt-to-Equity Ratio1.75 Current Ratio2.57 Quick Ratio2.43Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$29.56 million Price / Sales14.85 Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book18.67Profitability EPS (Most Recent Fiscal Year)($0.12) Net Income$-20,580,000.00 Net Margins-82.94% Return on Equity-114.36% Return on Assets-30.35%Miscellaneous Employees88 Outstanding Shares196,025,000Market Cap$439.10 million Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:DRRX Rates by TradingView Receive DRRX News and Ratings via Email Sign-up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter. DURECT (NASDAQ:DRRX) Frequently Asked Questions How has DURECT's stock been impacted by COVID-19 (Coronavirus)? DURECT's stock was trading at $1.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DRRX stock has increased by 35.8% and is now trading at $2.24. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of DURECT? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DURECT. When is DURECT's next earnings date? DURECT is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for DURECT. How were DURECT's earnings last quarter? DURECT Co. (NASDAQ:DRRX) posted its earnings results on Monday, May, 11th. The specialty pharmaceutical company reported ($0.05) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.01. The specialty pharmaceutical company had revenue of $2.78 million for the quarter, compared to analyst estimates of $4.74 million. DURECT had a negative return on equity of 114.36% and a negative net margin of 82.94%. View DURECT's earnings history. What price target have analysts set for DRRX? 5 brokers have issued 12-month price targets for DURECT's shares. Their forecasts range from $2.10 to $6.00. On average, they expect DURECT's stock price to reach $4.53 in the next year. This suggests a possible upside of 102.0% from the stock's current price. View analysts' price targets for DURECT. What are Wall Street analysts saying about DURECT stock? Here are some recent quotes from research analysts about DURECT stock: 1. According to Zacks Investment Research, "Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from the medical device and drug delivery industries with its proprietary pharmaceutical and biotechnology drug formulations. " (5/8/2020) 2. HC Wainwright analysts commented, "Recently Signed Gilead Partnership Yields First $10M Milestone; Affirm Buy Gilead rapidly advances long-acting injectible HIV drug based on SABER agreement. Yesterday, DURECT announced that it has earned a $10M milestone payment from Gilead (GILD; not rated) related to the further development of an investigational injectable HIV product utilizing DURECT’s SABER technology, as part of a license agreement that was announced in July 2019. In addition to the $25M upfront payment already received, remaining milestones include the potential for up to an additional $65M in development and regulatory milestones, up to an additional $70M in sales-based milestones, as well as tiered royalties on product sales." (9/10/2019) Has DURECT been receiving favorable news coverage? Press coverage about DRRX stock has been trending somewhat negative on Friday, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. DURECT earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about DURECT. Who are some of DURECT's key competitors? Some companies that are related to DURECT include Aurinia Pharmaceuticals (AUPH), Madrigal Pharmaceuticals (MDGL), Passage Bio (ZNTL), Akebia Therapeutics (AKBA), I-Mab (IMAB), INDIVIOR PLC/S (INVVY), Intra-Cellular Therapies (ITCI), Y-mAbs Therapeutics (YMAB), Zymeworks (ZYME), Ironwood Pharmaceuticals (IRWD), Zogenix (ZGNX), Epizyme (EPZM), Intercept Pharmaceuticals (ICPT), BELLUS Health (BLUSF) and Mersana Therapeutics (MRSN). View all competitors. What other stocks do shareholders of DURECT own? Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Novavax (NVAX), Cassava Sciences (SAVA), Catalyst Pharmaceuticals (CPRX), Gilead Sciences (GILD), Amarin (AMRN), Geron (GERN), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Verastem (VSTM) and Inovio Pharmaceuticals (INO). Who are DURECT's key executives? DURECT's management team includes the following people: Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 62)Mr. Matthew J. Hogan, CFO & Sec. (Age 59)Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 62)Mr. Michael H. Arenberg, Chief Financial Officer (Age 49)Dr. John W. Gibson B.S., M.S., VP of Birmingham Operations & Principal Scientist What is DURECT's stock symbol? DURECT trades on the NASDAQ under the ticker symbol "DRRX." How do I buy shares of DURECT? Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is DURECT's stock price today? One share of DRRX stock can currently be purchased for approximately $2.24. How big of a company is DURECT? DURECT has a market capitalization of $439.10 million and generates $29.56 million in revenue each year. The specialty pharmaceutical company earns $-20,580,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis. DURECT employs 88 workers across the globe. What is DURECT's official website? The official website for DURECT is www.durect.com. How can I contact DURECT? DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417 or via email at [email protected] This page was last updated on 7/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
